Latest Ticagrelor Stories
Emergency Department-Based Observational Study Aims to Fill Data Gaps in ACS Care Shrewsbury, NJ (PRWEB) October 27, 2014 The Hospital Quality Foundation
MarketOptimizer.org adds new report "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" to its store.
DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its
LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Scientists from the University of Sheffield have discovered ground breaking clues as to how the pioneering heart drug ticagrelor might reduce the risk of dying following a heart attack, in comparison to previous standard treatments.
Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel.